Company News

AMR is one of the most urgent public health challenges facing the world today. Drug-resistant infections make illnesses harder to treat, increase healthcare costs, prolong hospital stays, and contribute to preventable deaths.

At bioMérieux, we have a long-standing commitment to advancing microbial identification and helping laboratories make faster, more confident decisions. We are pleased to participate in MALDIBANK, an ambitious European Union-funded initiative designed to accelerate innovation in microbial identification through the integration of MALDI-TOF Mass Spectrometry, artificial intelligence, and cloud-based data infrastructure.

Respiratory infections remain a significant challenge for patients, healthcare professionals, and healthcare systems worldwide. From seasonal respiratory illnesses to more severe infections, clinicians often face complex decisions when evaluating patients whose similar symptoms can have many possible causes.

For patients at risk of sepsis, time matters. Faster diagnostic information can help healthcare teams identify the cause of infection sooner, supporting earlier better-informed care decisions.

With GENE-UP® PROBIOTIC SPECIES ID, bioMérieux introduces a first-of-its-kind commercialized species-level identification PCR solution for in-house quality control teams and external laboratory partners.